1. Indications and Usage
\nAlzheimer’s Disease:
\nIndicated for the treatment of mild cognitive impairment (MCI) or mild dementia stage of Alzheimer’s disease.
\nPatient Selection:
\nTreatment should be initiated in patients with mild cognitive impairment or mild dementia. The presence of amyloid beta (A\u03b2) pathology must be confirmed prior to starting treatment.
\n2. Dosage and Administration
\nRecommended Dosage:
\nAdults: 10 mg\/kg administered intravenously every 2 weeks.
\nAdministration Instructions:
\nPreparation: Must be diluted prior to use in 250 mL of 0.9% Sodium Chloride Injection. Gently invert to mix; do not shake.
\nInfusion: Administer via intravenous infusion over approximately 1 hour using an intravenous line with a 0.2-micron in-line filter.
\nStorage of Diluted Solution: If not used immediately, store at 2\u00b0C to 8\u00b0C or at room temperature (up to 30\u00b0C) for a maximum of 4 hours. Do not freeze.
\nDose Modifications & Monitoring:
\nMissed Dose: If a dose is missed, administer the next dose as soon as possible.
\nMRI Monitoring: Obtain a baseline brain MRI prior to initiating treatment. Perform additional MRIs prior to the 5th, 7th, and 14th infusions.
\nInfusion-Related Reactions (IRRs): Monitor patients during infusion. If an IRR occurs, reduce the infusion rate or stop the infusion and provide appropriate medical care.
\n3. Mechanism of Action
\nAnti-Amyloid Beta Monoclonal Antibody:
\nLecanemab is a recombinant humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody.
\nPhysiological Effect:
\nIt selectively targets and binds to large, soluble amyloid beta (A\u03b2) protofibrils (aggregated forms of A\u03b2). By neutralizing and clearing these neurotoxic A\u03b2 aggregates and plaques from the brain, it reduces amyloid pathology associated with Alzheimer’s disease.
\n4. Safety and Warnings
\nAmyloid Related Imaging Abnormalities (ARIA):
\nARIA-E (edema\/effusion) and ARIA-H (microhemorrhages and superficial siderosis) can occur. Most cases are asymptomatic, but serious and potentially fatal events have occurred. The risk of ARIA is significantly increased in patients who are Apolipoprotein E (ApoE) \u03b54 homozygotes.
\nInfusion-Related Reactions (IRRs):
\nSymptoms may include fever, chills, body aches, nausea, vomiting, hypotension, hypertension, and dyspnea. Monitor patients closely during administration.
\nHypersensitivity Reactions:
\nAngioedema and anaphylaxis have been reported. Discontinue lecanemab immediately if a serious hypersensitivity reaction occurs.
\n5. Adverse Reactions
\nMost Common:
\nInfusion-related reactions, ARIA-E (edema), ARIA-H (microhemorrhages), headache, and falls.
\n6. Drug Interactions
\nAnticoagulants and Antiplatelet Agents:
\nNo formal drug interaction studies have been conducted. However, because ARIA-H involves microhemorrhages, caution is advised when administering lecanemab to patients receiving anticoagulant or antiplatelet therapy.
\n7. Pharmaceutical Information
\nChemical Description:
\nLecanemab is a humanized IgG1 monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It has a molecular weight of approximately 150 kDa.
\nStorage and Handling:
\nStore vials refrigerated at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F) in the original carton to protect from light.
\nDo not freeze or shake.
\nEach single-dose vial is for one-time use only; discard any unused portion.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u4e50\u610f\u4fdd\u00ae (Leqembi\u00ae)
\nGeneric Name: Lecanemab Injection
\nStrength: 200mg per vial, 2mL per vial
\nManufacturer: Biogen US Corporation
\nMarketing Authorization Holder: Eisai Inc.
\nApproval Date in China: January 2024
\nRegistration Number: \u56fd\u836f\u51c6\u5b57 SJ20240001
\nStorage: Store at 2\u20138\u2103 in the original package; do not shake, avoid freezing, keep away from light, and keep out of reach of children<\/p>\n
Price&Cost:Contact Us now for the best price of Lecanemab Injection\uff08Leqembi\uff09<\/p>\n","protected":false},"featured_media":3153,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[92],"product_cat":[25],"product_tag":[],"class_list":["post-3150","product","type-product","status-publish","has-post-thumbnail","product_brand-eisai","product_cat-injection","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n